Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:56 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
NCT01841021 · H. Lee Moffitt Cancer Center and Research Institute · NA · terminated · last registry update 2017-01-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow accrual, loss of sponsor support” | – | Registry record, H. Lee Moffitt Cancer Center and Research Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TUBB4B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-01-04Phase 3 first posted: Janssen Research & Development, LLC, Erdafitinib + Vinflunine (NCT03390504)
- 2017-06-14Results posted on the registry: Dana-Farber Cancer Institute, asparaginase + cyclophosphamide (NCT00400946)
- 2017-06-14Results posted on the registry: Children's Oncology Group, Cyclophosphamide + Dactinomycin (NCT00379340)
- 2017-05-12Phase 3 first posted: Alliance for Clinical Trials in Oncology, Allopurinol + Cytarabine (NCT03150693)
- 2017-04-26Results posted on the registry: National Cancer Institute (NCI), Cyclophosphamide + Cytarabine (NCT00792948)
- 2017-04-25Phase 3 first posted: Children's Oncology Group, Busulfan + Carboplatin (NCT03126916)
- 2017-01-13Phase 3 first posted: Dana-Farber Cancer Institute, Pegaspargase + Erwinia asparaginase (NCT03020030)
- 2017-01-02Phase 3 first posted: Children's Oncology Group, Calaspargase Pegol + Cyclophosphamide (NCT03007147)
- 2016-12-13Phase 3 first posted: ETOP IBCSG Partners Foundation, Pembrolizumab + Gemcitabine (NCT02991482)
- 2016-10-31Results posted on the registry: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin Hydrochloride (NCT00972478)
- 2016-10-19Results posted on the registry: St. Jude Children's Research Hospital, vincristine + doxorubicin (NCT01946529)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision